Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:

Free Newsletter

  Email address:

BioTime Inks Progenitor Cell Distribution Deal for China

publication date: Dec 9, 2010
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
BioTime of California has signed up Shanghai Genext Medical Technology as the China marketer of its ACTCellerate™ cell lines, a highly purified source of progenitor cells. Genext will also sell BioTime’s cell cultures, which are customized for each line. ACTCellerate™ is BioTime’s proprietary technology that allows the expansion of over 140 highly-purified primitive human embryonic progenitor cells (hEPCs) from hES or induced pluripotent stem (iPS) cells. More details....

Stock Symbol: (NYSE Amex: BTX)

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...